Last reviewed 2026-04-22 · How we verify

Bladder instillation WITHOUT triamcinolone acetonide

Olivia Cardenas-Trowers, M.D. · Phase 3 active Small molecule

Bladder instillation WITHOUT triamcinolone acetonide is a Small molecule drug developed by Olivia Cardenas-Trowers, M.D.. It is currently in Phase 3 development for Bladder pain syndrome / Interstitial cystitis (likely primary indication).

A bladder instillation therapy that delivers therapeutic agents directly into the bladder without triamcinolone acetonide to treat bladder conditions.

A bladder instillation therapy that delivers therapeutic agents directly into the bladder without triamcinolone acetonide to treat bladder conditions. Used for Bladder pain syndrome / Interstitial cystitis (likely primary indication).

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Bladder instillation WITHOUT triamcinolone acetonide
Sponsor	Olivia Cardenas-Trowers, M.D.
Modality	Small molecule
Therapeutic area	Urology
Phase	Phase 3

Mechanism of action

Bladder instillation is a local delivery method where medication is introduced directly into the bladder via catheter, allowing high local concentrations while minimizing systemic exposure. This formulation specifically excludes triamcinolone acetonide (a corticosteroid), suggesting it may contain alternative active agents or be a vehicle/comparator formulation. The direct instillation approach is commonly used for interstitial cystitis, bladder pain syndrome, and recurrent urinary tract infections.

Approved indications

Bladder pain syndrome / Interstitial cystitis (likely primary indication)

Common side effects

Dysuria
Urinary frequency
Bladder spasm
Hematuria

Key clinical trials

Clinical Trial Comparing Two Bladder Instillations for IC/BPS (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bladder instillation WITHOUT triamcinolone acetonide CI brief — competitive landscape report
Bladder instillation WITHOUT triamcinolone acetonide updates RSS · CI watch RSS
Olivia Cardenas-Trowers, M.D. portfolio CI

Frequently asked questions about Bladder instillation WITHOUT triamcinolone acetonide

What is Bladder instillation WITHOUT triamcinolone acetonide?

Bladder instillation WITHOUT triamcinolone acetonide is a Small molecule drug developed by Olivia Cardenas-Trowers, M.D., indicated for Bladder pain syndrome / Interstitial cystitis (likely primary indication).

How does Bladder instillation WITHOUT triamcinolone acetonide work?

A bladder instillation therapy that delivers therapeutic agents directly into the bladder without triamcinolone acetonide to treat bladder conditions.

What is Bladder instillation WITHOUT triamcinolone acetonide used for?

Bladder instillation WITHOUT triamcinolone acetonide is indicated for Bladder pain syndrome / Interstitial cystitis (likely primary indication).

Who makes Bladder instillation WITHOUT triamcinolone acetonide?

Bladder instillation WITHOUT triamcinolone acetonide is developed by Olivia Cardenas-Trowers, M.D. (see full Olivia Cardenas-Trowers, M.D. pipeline at /company/olivia-cardenas-trowers-m-d).

What development phase is Bladder instillation WITHOUT triamcinolone acetonide in?

Bladder instillation WITHOUT triamcinolone acetonide is in Phase 3.

What are the side effects of Bladder instillation WITHOUT triamcinolone acetonide?

Common side effects of Bladder instillation WITHOUT triamcinolone acetonide include Dysuria, Urinary frequency, Bladder spasm, Hematuria.

Manufacturer: Olivia Cardenas-Trowers, M.D. — full pipeline
Therapeutic area: All drugs in Urology
Indication: Drugs for Bladder pain syndrome / Interstitial cystitis (likely primary indication)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing